Literature DB >> 7010092

Malariotherapy and cancer.

L B Greentree.   

Abstract

Malariotherapy merits a clinical trial as an adjuvant to conventional cancer therapy. This particular modality of treatment is a most potent stimulus of macrophage activity. These scavenger cells are widely believed to be an essential arm in the host's immune defenses against malignant disease, both as regards the processing of antigens and as killers of tumor cells. Significant too, malariotherapy, as formerly used to effectively treat some 16,000 patients with paretic neurosyphilis in one institution alone, before the advent of the penicillin age, has proved to be a particularly safe modality of treatment.

Entities:  

Mesh:

Year:  1981        PMID: 7010092     DOI: 10.1016/0306-9877(81)90019-0

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  4 in total

1.  Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity.

Authors:  Lili Chen; Zhengxiang He; Li Qin; Qinyan Li; Xibao Shi; Siting Zhao; Ling Chen; Nanshan Zhong; Xiaoping Chen
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

2.  Worldwide malaria incidence and cancer mortality are inversely associated.

Authors:  Li Qin; Changzhong Chen; Lili Chen; Ran Xue; Ming Ou-Yang; Chengzhi Zhou; Siting Zhao; Zhengxiang He; Yu Xia; Jianxing He; Pinghua Liu; Nanshan Zhong; Xiaoping Chen
Journal:  Infect Agent Cancer       Date:  2017-02-14       Impact factor: 2.965

Review 3.  Microneedle arrays integrated with living organisms for smart biomedical applications.

Authors:  Bo Cai; Yusheng Gong; Zheng Wang; Lin Wang; Wei Chen
Journal:  Theranostics       Date:  2021-10-25       Impact factor: 11.556

4.  Plasmodium infection inhibits tumor angiogenesis through effects on tumor-associated macrophages in a murine implanted hepatoma model.

Authors:  Benfan Wang; Qinyan Li; Jinyan Wang; Siting Zhao; Bayaer Nashun; Li Qin; Xiaoping Chen
Journal:  Cell Commun Signal       Date:  2020-09-24       Impact factor: 5.712

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.